Search
Tianeptine
go.drugbank.com/drugs/DB09289InvestigationalAsia (including Singapore) and Latin America as “Stablon” and “Tatinol” but it is not available in Australia, Canada, New Zealand, the U.K. or the U.S. … Currently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in several other European countries under the trade name “Coaxil” as well as in
Tofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.
Samidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational, and a longer half-life, making it an attractive candidate for oral dosing. … [Olanzapine] is an effective atypical antipsychotic that, like other antipsychotics, is associated with weight gain, metabolic dysfunction, and increased risk of type II diabetes.
Anthoxanthum odoratum
go.drugbank.com/drugs/DB14163ApprovedAnthoxanthum odoratum allergenic extract is used in allergenic testing.
Mixtures: ORALAIR 100 IR + 300 IR Sublingualtabletten, ORALAIR 100 IR + 300 IR SublingualtablettenNialamide
go.drugbank.com/drugs/DB04820ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.
Fosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalIn April 2018, the U.S. … Fosnetupitant is the pro-drug form of netupitant [FDA label].
Categories: Substance P/Neurokinin-1 Receptor AntagonistOcrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalIt was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. … [A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA.
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).
Categories: Programmed Death Receptor-1 Blocking AntibodyQuaternium-15
go.drugbank.com/drugs/DB14198ApprovedIt is an anti-microbial agent by virtue of being a formaldehyde releaser, however this can also cause contact dermatitis, a symptom of an allergic reaction, especially in those with sensitive skin. … Quaternium-15 is a quaternary ammonium salt used as a surfactant and preservative in many products including cosmetics.